Financial Performance - Hubei Gongtong Pharmaceutical Co., Ltd. expects a net loss attributable to shareholders of between 58 million and 75 million yuan for the fiscal year 2025[1]. Gross Margin and Costs - The decline in gross margin compared to the same period last year is attributed to slight decreases in market prices of certain products and higher unit costs due to new projects not fully releasing capacity[2]. Research and Development - Increased R&D investment has led to a rise in R&D expenses[2]. Interest Expenses - Interest expenses have increased due to the cessation of capitalization of interest on convertible bonds and project-specific loans after the fundraising projects were completed[2].

证券代码：920344 证券简称：三元基因 公告编号：2026-006 北京三元基因药业股份有限公司 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 单位：元 项目 本报告期 上年同期 变动比例% 营业收入 285,997,870.92 256,541,927.31 11.48% 利润总额 4,111,260.65 24,446,609.27 -83.18% 归属于上市公司股东的 净利润 5,439,497.38 22,172,865.71 -75.47% 归属于上市公司股东的 扣除非经常性损益的净 利润 3,762,019.98 19,722,159.29 -80.92% 基本每股收益 0.04 0.18 -77.78% 加权平均净资产收益 率%（扣非前） 0.8 ...

证券代码：920266 证券简称：生物谷 公告编号：2026-004 云南生物谷药业股份有限公司 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 报告期内，公司预计实现营业收入 433,022,351.34 元，同比下 降 16.12%；归属于上市公司股东的净利润为-55,846,879.39 元，同 比减亏 24.94%；归属于上市公司股东的扣除非经常性损益的净利润 为-59,424,909.68 元，同比减亏 25.92%；基本每股收益为-0.45 元， 同比减亏 25.00%。 报告期末，公司总资产为 1,058,328,094.68 元，较期初减少 7.57% ；归属于上市公司股东的所有者权益为 876,533,308.42 元， 较期初减少 5.25%；归属于上市公司股东的每股净资产为 7.07 元， 较期初减少 5.23%。 （二）业绩变动的主要原因 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数 据，未经会计师事务所审计，具体数据以公司 202 ...

证券代码：688280 证券简称：精进电动 公告编号：2026-004 精进电动科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经精进电动科技股份有限公司（以下简称"公司"）财务部门初步测算， 预计 2025 年年度实现营业收入 245,370.00 万元到 299,800.00 万元；与上年同 期相比增加 114,879.94 万元到 169,309.94 万元，与上年同期相比增加 88.04% 到 129.75%。 2、归属于母公司所有者的净利润与上年同期（法定披露数据）相比，将实 现扭亏为盈，实现归属于母公司所有者的净利润 13,710.00 万元到 18,490.00 万元；与上年同期相比将增加 57,351.33 万元到 62,131.33 万元，同比增加 131.42%到 142.37%。 3、归属于母公司所有者扣除非经常性损益后的净利 ...

证券代码：920026 证券简称：卓兆点胶 公告编号：2026-006 苏州卓兆点胶股份有限公司 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 报告期内，公司营业收入、归属于上市公司股东的净利润、归属于上市公司 股东的扣除非经常性损益后的净利润以及基本每股收益均实现较大幅度增长，主 要原因为：1、公司稳步推进存量项目验收落地，贡献营收与利润超千万元；2、 原果链业务凭借成熟的技术积淀与完善的服务能力，经营态势稳健，营收及业绩 规模保持稳定；3、2024 年前瞻布局的新兴业务迎来业绩兑现，其中 Meta AI 眼 镜业务领域成效显著，报告期内公司通过集成厂商及代工厂，间接向 Meta 供应 精密点胶阀，实现营业收入与净利润超千万元；4、控股子公司广东浦森塑胶科 技有 ...

证券代码：920478 证券简称：峆一药业 公告编号：2026-003 安徽峆一药业股份有限公司 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 （二）业绩变动的主要原因 1、报告期内，公司持续深化业务布局与市场开拓，积极应对外部环境变化， 稳步扩大市场份额、优化产品销售结构，有效提升了市场竞争力与整体盈利水平。 2、公司 2024 年实施股权激励计划，2025 年度对相关股份支付费用进行全 年摊销，致使本期费用同比增加，进而对本期净利润增幅产生一定影响。 一、2025 年年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 287,684,655.66 | 270,466,229.84 | 6.3 ...

Revenue Performance - In Q1 2025, flooring revenue was RMB 2,668.60 million, accounting for 7.62% of total revenue, a decrease of 39.21% compared to RMB 4,389.57 million in Q1 2024[4] - Total revenue for 2025 was RMB 35,633.06 million, representing a 5.98% increase from RMB 33,621.00 million in 2024[4] - The flooring segment contributed RMB 26,467.86 million in 2025, making up 75.58% of total revenue, down from 79.59% in 2024[5] - Cabinet furniture revenue in Q2 2025 increased by 159.32% to RMB 1,740.22 million compared to RMB 671.06 million in Q2 2024[4] - The total revenue from the door and wood panel segment in Q4 2025 was RMB 3,521.15 million, a significant increase of 245.78% from RMB 1,018.31 million in Q4 2024[4] - The company reported a total of RMB 3,389.71 million in cabinet furniture revenue for 2025, a decrease of 25.95% from RMB 4,577.41 million in 2024[4] - The overall revenue from other business segments decreased by 46.27% to RMB 612.01 million in 2025 from RMB 1,139.05 million in 2024[4] Revenue Recognition Policies - The company confirmed that its revenue recognition policy remains compliant with accounting standards, with no changes reported during the period[10] - The company’s revenue recognition policy states that income is recognized when control of the product is transferred to the customer, ensuring compliance with relevant accounting standards[11] - The company emphasized that there were no instances of premature or deferred revenue recognition to avoid delisting risk warnings[11] - The revenue recognition policy includes a 15-day payment window after project completion, ensuring cash flow management[21] - The company confirmed that revenue recognition for engineering projects is based on the receipt of acceptance or settlement documents[24] - The revenue recognition for projects is based on signed delivery notes, emphasizing the importance of contract management[30] - The company confirmed that there are no revenues recognized that lack commercial substance or are derived from non-genuine transactions[45] Accounts Receivable Management - The company reported a total accounts receivable of 11,195.04 million, with a net increase of 249.89 million compared to the previous period[15] - The accounts receivable balance being negative is due to advance payments from customers, primarily for project progress payments according to contracts[16] - The company has a payment policy where 20% is paid before shipment, 70% during project progress, and the remaining 10% upon project completion[15] - The company reported a decrease in accounts receivable from certain clients, with specific amounts noted, such as a decrease of 41.28 million from one client[15] - The accounts receivable for the top customer decreased by 1,723.89 million RMB, indicating improved cash collection efforts[21] - The total accounts receivable for the top ten customers increased by 2,863.80 million RMB, while the total accounts receivable at the end of the period was 2,250.83 million RMB[19] - The company is actively monitoring its revenue recognition practices to avoid any premature or cross-period revenue recognition that could lead to delisting risks[23] - The company is actively managing its accounts receivable, with a focus on timely collections to improve liquidity[28] Customer and Market Expansion - The company has added new customers in 2025, which previously had no revenue, indicating a potential growth in revenue streams[16] - The company is focused on expanding its market presence through direct sales to engineering clients, which includes installation responsibilities[15] - The company anticipates continued revenue growth from its existing customer base and new clients in the upcoming fiscal year[16] - The company is focusing on expanding its market presence through strategic partnerships and direct sales to engineering clients[19] - The company is focusing on expanding its market presence through strategic partnerships and project collaborations in the construction and decoration sectors[34] Financial Performance and Strategy - The company reported a total revenue of 5,163.48 million RMB, with a net loss of 899.75 million RMB for the current period[22] - The company's total revenue for the year 2025 is reported at RMB 35,633.06 million, with revenue deductions amounting to RMB 732.04 million, representing 2.05% of total revenue[45] - The revenue deductions include RMB 519.94 million from other business activities outside normal operations, and RMB 212.10 million from newly added trade business[45] - The company has ongoing projects with a total contract value of 909.19 million RMB for the Dali Silver Bridge International Tourism Project, with expected revenue recognition in December 2025[26] - The total contract amount for various projects is 7,904.74 million RMB, with a revenue recognition of 7,388.79 million RMB, resulting in a decrease of 2,888.12 million RMB[28] - The company has a projected accounts receivable balance of 3,289.80 million RMB by the end of 2025, with a current period addition of 1,912.32 million RMB[28] - The company has completed the settlement for various projects, indicating a strong cash flow position with significant amounts settled[36] Related Party Transactions and Audits - The company has engaged in related party transactions with Dali Jiapeng Construction Engineering Co., Ltd., with multiple contracts signed in September 2024[34] - The company has executed various audit procedures to ensure the fairness and commercial substance of related party transactions, with no abnormalities found so far[43] - The company is currently undergoing an audit of its financial statements for the year 2025, with a focus on revenue recognition and related party transactions[47] - The company plans to complete further audits and provide clear opinions on related matters by April 25, 2026[43]

证券代码：688571 证券简称：杭华股份 公告编号：2026-004 注：1.本报告期初数同法定披露的上年年末数。 2.以上财务数据及指标以合并报表数据填制但未经审计，最终结果以公司 2025 年年度报告披露为准。 二、经营业绩和财务状况情况说明 杭华油墨股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特别提示： 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以杭华油墨股份有限公司（以下简称"公司"或"杭华股份"）2025 年年度报告披露为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 1 单位：元 币种：人民币 项目 本报告期 上年同期 增减变动幅度（%） 营业总收入 1,249,380,701.66 1,269,844,123.27 -1.61 营业利润 117,787,955.71 160,894,566.09 -26.79 利润总额 117,274,332.83 160,640,659.49 -27.00 归属于 ...

A 股代码：600015 A 股简称：华夏银行 编号：2026-04 2、2025年6月及9月，本行分别向永续债持有人支付利息人民币9.84亿元及4.46亿元，共 计14.30亿元。在计算基本每股收益及加权平均净资产收益率时，本行考虑了支付永续债利 息的影响。 1 二、经营业绩和财务状况情况说明 华夏银行股份有限公司2025年度业绩快报公告 本行董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公告所载2025年度主要财务数据为华夏银行股份有限公司（以下简称"本 行"）初步核算的集团口径数据，未经会计师事务所审计，具体数据以本行2025 年年度报告披露的数据为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：人民币百万元 | 项目 | 年 2025 | 年 2024 | 增减变动幅度（%） | | | --- | --- | --- | --- | --- | | | （未经审计） | （经审计） | | | | 营业收入 | 91,914 | 97,146 | | -5.39 | | 营业利润 | 34,28 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以公司2025年年度的定期报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 注：1.本报告期初数同法定披露的上年年末数。 证券代码：688670 证券简称：金迪克 公告编号：2026-003 江苏金迪克生物技术股份有限公司 2025 年度业绩快报公告 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 公司 2025 年实现营业收入 11,323.18 万元，同比增长 40.13%；实现归属于 母公司所有者的净利润-17,347.36 万元，同比增亏 85.53%；实现归属于母公司所 有者的扣除非经常性损益的净利润-18,000.28 万元，同比增亏 69.46%。 截至 2025 年 12 月 31 日，公司总资产 142,189.87 万元，较报告期初下降 7.24%；归属于母公司的所有者权益 109,998.72 万元，较报告期初下降 13.90%。 报告期内 ...